profit from every $100 of sales.
$0$100
Cue Biopharma
$20.14+7.53% today
-4.3% in 1 year
1-year low $5.311-year high $37.84
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Cue Biopharma sold, what it kept, and what it did with the cash.
Sales went from $1.25 million in 2022 to $27.5 million in 2025, with -$26.6 million of profit last year.
SalesProfit
Cue Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cue Biopharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Cue Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 5 | 9 | 27 | |
| – | – | – | – | |
| -54 | -52 | -42 | -27 | |
| -50 | -46 | -38 | -22 | |
| -53 | -51 | -41 | -27 | |
| -44.70 | -33.30 | -21.60 | -8.40 | |
| – | – | – | – | |
| -4,297.3% | -947.0% | -447.9% | -96.6% | |
| -4,257.8% | -924.1% | -438.0% | -96.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 91 | 62 | 32 | 42 |
| Cash | 52 | 49 | 22 | 27 |
| Total debt | 19 | 15 | 9 | 4 |
| Total liabilities | 26 | 24 | 15 | 16 |
| 66 | 37 | 17 | 26 | |
| 1 | 2 | 2 | 3 | |
| -48.6% | -75.5% | -119.4% | -66.4% | |
| -80.7% | -136.8% | -232.4% | -100.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -42 | -40 | -36 | -22 | |
| 0 | – | 0 | 0 | |
| -42 | -40 | -36 | -22 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 8 | 7 | 5 |
Valuation
- –
- –
- –
- 4.8×
- 5.3×
- –
- –
- -14.9%
- -18.2%
- 0.0%
Profitability
- 88.0%
- -96.6%
- -96.9%
- -83.9%
- -86.6%
- -91.7%
- -165.2%
- -63.0%
- -92.3%
- 137.2%
Growth
- +180.5%
- –
- +39.9%
- –
- +31.9%
Financial health
- -1.0×
- 0.16
- 9.9%
- -74.3×
- 2.74
- 2.74
- 0.65
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 948
Bottom 4%of 871
Top 2%of 868
Bottom 7%of 985
What analysts expect
- Average price target
- $4.33
- Range
- $2.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -1.08 | -3.30 | +67.3% |
| Mar 16, 2026 | 0.30 | -2.70 | +111.1% |
| Nov 12, 2025 | -0.07 | -0.10 | +30.0% |
| Aug 12, 2025 | -0.09 | -0.13 | +30.8% |
| May 12, 2025 | -0.17 | -0.14 | −21.4% |
| Mar 31, 2025 | -0.13 | -0.16 | +18.8% |
| Nov 14, 2024 | -0.17 | -0.20 | +15.0% |
| Aug 19, 2024 | -0.20 | -0.29 | +31.0% |
News
The big winners of the tech wreck are biopharma stocksMarketWatch · Oct 30, 2026Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregationSeeking Alpha · Sep 25, 2026Chinese biopharma stocks jump as U.S. weighs keeping door open to drug dealsCNBC · Sep 21, 2026Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rallyMarketWatch · Aug 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
40No pass
Benjamin Graham
39No pass
Philip Fisher
47No pass
Peter Lynch
49No pass
Joel Greenblatt
2No pass
Charlie Munger
38No pass
Terry Smith
36No pass
Questions about Cue Biopharma
Is Cue Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cue Biopharma AI analysis
What does Cue Biopharma do?
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. It is in Biotechnology.
Does Cue Biopharma pay a dividend?
No. Cue Biopharma does not pay a dividend at the moment.
Is Cue Biopharma stock halal?
Yes. Cue Biopharma passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Cue Biopharma stock done over the past year?
Down 4.3% over the past twelve months, to $20.14. It traded between $5.31 and $37.84 and is 46.8% below its high.
Who are Cue Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Cue Biopharma's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.